Bionano Genomics Inc (BNGO) — Cash Flow-to-Debt Ratio
Bionano Genomics Inc (BNGO) has a Cash Flow-to-Debt Ratio of -0.14x as of December 2025, meaning its operating cash flow of $-4.17 Million could theoretically repay 0% of its total liabilities ($29.16 Million) in one year. See BNGO current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Bionano Genomics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Bionano Genomics Inc across 10 annual periods. Also explore Bionano Genomics Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Bionano Genomics Inc (2016–2025)
Year-by-year debt coverage analysis for Bionano Genomics Inc. For market capitalisation and broader financial context, see BNGO company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.56x | $-16.34 Million | $29.16 Million | ▲ +66.4% |
| 2024 | -1.67x | $-68.92 Million | $41.30 Million | ▼ -57.7% |
| 2023 | -1.06x | $-125.18 Million | $118.25 Million | ▲ +50.7% |
| 2022 | -2.15x | $-124.82 Million | $58.10 Million | ▼ -19.4% |
| 2021 | -1.80x | $-71.93 Million | $39.98 Million | ▼ -19.1% |
| 2020 | -1.51x | $-38.31 Million | $25.37 Million | ▼ -36.0% |
| 2019 | -1.11x | $-29.53 Million | $26.59 Million | ▲ +18.4% |
| 2018 | -1.36x | $-19.94 Million | $14.67 Million | ▼ -294.4% |
| 2017 | -0.34x | $-20.82 Million | $60.37 Million | ▲ +38.3% |
| 2016 | -0.56x | $-23.50 Million | $42.05 Million | — |